238 related articles for article (PubMed ID: 27087977)
1. Successful treatment of hepatic oligometastases with stereotactic ablative radiotherapy and radiofrequency ablation in an anaplastic lymphoma kinase fusion-positive lung cancer patient.
Weber B; Liu M; Sobkin P; Morris SW; Hout D; van der Westhuizen N; Tonseth RP; Saltman DL
J Med Radiat Sci; 2016 Mar; 63(1):67-70. PubMed ID: 27087977
[TBL] [Abstract][Full Text] [Related]
2. Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.
Wang W; Sun X; Hui Z
Oncol Res Treat; 2019; 42(11):599-606. PubMed ID: 31527380
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic Body Radiotherapy and Ablative Therapies for Lung Cancer.
Abbas G; Danish A; Krasna MJ
Surg Oncol Clin N Am; 2016 Jul; 25(3):553-66. PubMed ID: 27261915
[TBL] [Abstract][Full Text] [Related]
4. Does lung cancer mutation status and targeted therapy predict for outcomes and local control in the setting of brain metastases treated with radiation?
Wang TJ; Saad S; Qureshi YH; Jani A; Nanda T; Yaeh AM; Rozenblat T; Sisti MB; Bruce JN; McKhann GM; Lesser J; Halmos B; Stoopler MB; Lassman AB; Cheng SK; Isaacson SR
Neuro Oncol; 2015 Jul; 17(7):1022-8. PubMed ID: 25910841
[TBL] [Abstract][Full Text] [Related]
5. [Role of stereotactic radiotherapy in the treatment of oligometastatic colorectal cancer].
Pouypoudat C; Trouette R; Bernard B; Vendrely V
Cancer Radiother; 2021 Oct; 25(6-7):523-525. PubMed ID: 34454836
[TBL] [Abstract][Full Text] [Related]
6. Local Ablative Therapies in Oligometastatic NSCLC: New Data and New Directions.
Lang P; Gomez DR; Palma DA
Semin Respir Crit Care Med; 2020 Jun; 41(3):369-376. PubMed ID: 32450591
[TBL] [Abstract][Full Text] [Related]
7. Radiation Therapy for Oligometastatic Non-Small Cell Lung Cancer: Theory and Practice.
Rusthoven CG; Yeh N; Gaspar LE
Cancer J; 2015; 21(5):404-12. PubMed ID: 26389766
[TBL] [Abstract][Full Text] [Related]
8. Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer.
Juan O; Popat S
Clin Lung Cancer; 2017 Nov; 18(6):595-606. PubMed ID: 28377206
[TBL] [Abstract][Full Text] [Related]
9. Management of CNS disease in ALK-positive non-small cell lung cancer: Is whole brain radiotherapy still needed?
Wrona A
Cancer Radiother; 2019 Sep; 23(5):432-438. PubMed ID: 31331844
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer.
Kissel M; Martel-Lafay I; Lequesne J; Faivre JC; Le Péchoux C; Stefan D; Barraux V; Loiseau C; Grellard JM; Danhier S; Lerouge D; Chouaid C; Gervais R; Thariat J
BMC Cancer; 2019 Dec; 19(1):1237. PubMed ID: 31856742
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneity of anaplastic lymphoma kinase gene rearrangement in non-small-cell lung carcinomas: a comparative study between small biopsy and excision samples.
Abe H; Kawahara A; Azuma K; Taira T; Takase Y; Fukumitsu C; Murata K; Yamaguchi T; Akiba J; Ishii H; Okamoto I; Hoshino T; Takamori S; Kage M
J Thorac Oncol; 2015 May; 10(5):800-805. PubMed ID: 25898958
[TBL] [Abstract][Full Text] [Related]
12. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.
Dubey AP; Pathi N; Viswanath S; Rathore A; Pathak A; Sud R
Indian J Cancer; 2017; 54(1):203-208. PubMed ID: 29199691
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
Sgambato A; Casaluce F; Maione P; Gridelli C
Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
[TBL] [Abstract][Full Text] [Related]
14. ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity.
Kimura H; Nakajima T; Takeuchi K; Soda M; Mano H; Iizasa T; Matsui Y; Yoshino M; Shingyoji M; Itakura M; Itami M; Ikebe D; Yokoi S; Kageyama H; Ohira M; Nakagawara A
Lung Cancer; 2012 Jan; 75(1):66-72. PubMed ID: 21757253
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic body radiation therapy for oligometastases.
Lo SS; Fakiris AJ; Teh BS; Cardenes HR; Henderson MA; Forquer JA; Papiez L; McGarry RC; Wang JZ; Li K; Mayr NA; Timmerman RD
Expert Rev Anticancer Ther; 2009 May; 9(5):621-35. PubMed ID: 19445579
[TBL] [Abstract][Full Text] [Related]
16. Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors.
Wrona A; Dziadziuszko R; Jassem J
Cancer Treat Rev; 2018 Dec; 71():59-67. PubMed ID: 30366200
[TBL] [Abstract][Full Text] [Related]
17. Targeted sequencing and intracranial outcomes of patients with lung adenocarcinoma brain metastases treated with radiotherapy.
Press RH; Zhang C; Cassidy RJ; Ferris MJ; Zhong J; Steuer CE; Pillai RN; Owonikoko TK; Kahn S; Ramalingam SS; Patel PR; Curran WJ; Shu HG; Sica GL; Higgins KA
Cancer; 2018 Sep; 124(17):3586-3595. PubMed ID: 30120912
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness Analysis of Stereotactic Ablative Body Radiation Therapy Compared With Surgery and Radiofrequency Ablation in Two Patient Cohorts: Metastatic Liver Cancer and Hepatocellular Carcinoma.
Jin H; Chalkidou A; Hawkins M; Summers J; Eddy S; Peacock JL; Coker B; Kartha MR; Good J; Pennington M;
Clin Oncol (R Coll Radiol); 2021 Mar; 33(3):e143-e154. PubMed ID: 32951952
[TBL] [Abstract][Full Text] [Related]
19. The role of local ablative therapy in oligometastatic non-small-cell lung cancer: hype or hope.
Bansal P; Rusthoven C; Boumber Y; Gan GN
Future Oncol; 2016 Dec; 12(23):2713-2727. PubMed ID: 27467543
[TBL] [Abstract][Full Text] [Related]
20. Oligometastatic breast cancer: where are we now and where are we headed?-a narrative review.
Kent CL; McDuff SGR; Salama JK
Ann Palliat Med; 2021 May; 10(5):5954-5968. PubMed ID: 32921069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
